Standard
FDA Approves New Treatments for MCT8 Deficiency and Type 2 Diabetes While Advancing Breast Cancer Support Therapies
The United States Food and Drug Administration (FDA) closed the month of September with a series of landmark decisions that significantly expand the therapeutic landscape for endocrine-related disorders. These regulatory actions include the first-ever approval for a rare genetic condition known as MCT8 deficiency, the authorization of a once-weekly basal insulin for type 2 diabetes,…
